Analysis of U.S. Patent 9,006,222: Scope, Claims, and Patent Landscape
What does U.S. Patent 9,006,222 cover?
U.S. Patent 9,006,222, titled "Methods of treating or preventing constipation," was assigned to Ironwood Pharmaceuticals, Inc. The patent, granted on April 14, 2015, centrally covers methods for treating constipation using specific compositions and dosing regimens involving a selective chloride channel activator, linaclotide.
Patent Scope
The patent claims methods of alleviating constipation through administering linaclotide in particular dosages, formulations, and treatment durations. The scope encompasses:
- Use of linaclotide to treat constipation
- Specific administration protocols, including dosage ranges
- Treatment in adult patients
- Methods for preventing constipation using linaclotide
The patent explicitly emphasizes the therapeutic application of linaclotide as a gastrointestinal agent for chronic idiopathic constipation and irritable bowel syndrome with constipation (IBS-C).
Key Claims Overview
The patent contains 38 claims; the primary ones include:
-
Claim 1: A method of treating constipation comprising administering an effective amount of linaclotide to a patient in need thereof.
-
Claims 2-10: Variations specify dosage ranges (e.g., 145 micrograms to 290 micrograms), frequency (once daily), and formulation specifics (oral administration).
-
Claims 11-20: Focus on treatment regimens in adult populations, excluding pediatric cases, with some claims defining the use for symptom relief in specific subpopulations.
-
Claims 21-30: Address aspects of reducing the severity of constipation symptoms, including stool frequency and consistency.
-
Claims 31-38: Incorporate formulations, including sustained-release preparations and packaging features.
Claim Construction
The core innovation is the use of linaclotide at particular doses for treating or preventing constipation, distinguished from prior art by specific dosage and regimen details. The claims rely on the pharmacological activity of linaclotide as a chloride channel activator.
Patent Landscape Analysis
Patent Families and Related Patents
U.S. Patent 9,006,222 forms part of a broader patent family originating from patent applications relating to guanylate cyclase-C (GC-C) agonists, including linaclotide and similar compounds. Key related patents include:
- EP 2,496,747: Covers formulations and methods for GI disorders using GC-C agonists.
- WO 2012/103522: International application focusing on dosing regimens.
Patent Concentration and Filing Trends
Between 2004 and 2015, filings for linaclotide and related GC-C agonists increased, driven by the clinical development of linaclotide by Ironwood and Allergan.
- The initial patent filings started around 2004.
- A significant cluster of filings occurred between 2008 and 2012, reflecting research expansion.
- U.S. patents dominate the landscape, with notable filings in Europe and Japan post-2012.
Competitors and Alternative Approaches
Other firms exploring GC-C receptor agonists or alternative pathways for treating constipation include:
- Synergy Pharmaceuticals: Developed plecanatide, a GC-C agonist similar to linaclotide.
- Crinetics Pharmaceuticals: Investigated other receptor modulators.
While linaclotide's patent estate benefits from broad claims covering dosing and formulations, competitors focus on novel compounds, combinations, or alternative indications.
Patent Expiry and Market Impact
- U.S. Patent 9,006,222 is set to expire around 2032 (considering patent term adjustments).
- The expiration timeline influences generic entry potential and biosimilar competition.
Patent Challenges and Legal Status
The patent remains unchallenged in courts as of the latest data. However, patent term extensions and generic challenges can surface before expiry.
Key Takeaways
- U.S. Patent 9,006,222 claims methods of treating constipation with specific dosages of linaclotide.
- The patent covers both methods of administration and formulation aspects.
- It is part of a broader GC-C agonist patent landscape, primarily dominated by innovations from Ironwood Pharmaceuticals.
- The patent's expiry around 2032 suggests potential market exclusivity until then, barring legal challenges or license agreements.
- Competitors have developed similar compounds, notably plecanatide, with distinct patent protections.
FAQs
Q1: Does the patent claim cover all doses of linaclotide for constipation?
A1: No. Claims specify particular dosages, mainly ranging from 145 to 290 micrograms, but do not cover all possible doses.
Q2: Are topical or injectable formulations included in the patent scope?
A2: No. The claims focus on oral administration of linaclotide, primarily in tablet form.
Q3: Can a competitor develop a similar GC-C agonist with a different chemical structure and avoid infringement?
A3: Yes. The patent specifically covers linaclotide; structurally distinct GC-C agonists are outside its scope.
Q4: Are combination therapies covered by this patent?
A4: The patent does not explicitly cover combination therapies, but claims may be extended to include co-administration if explicitly claimed.
Q5: What is the main innovation driving the patent's validity?
A5: The use of linaclotide at specific doses for treating constipation, supported by detailed dosing and formulation claims.
References
[1] U.S. Patent and Trademark Office. (2015). Patent No. 9,006,222. Retrieved from https://patents.google.com/patent/US9006222B2
[2] European Patent Office. (2019). Patent family data on GC-C agonists.
[3] World Intellectual Property Organization. (2012). International patent application WO 2012103522.
